ZG006

ZG006 is an investigational agent whose form is not stated in the registry developed by Suzhou Zelgen Biopharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: ZG006 will be administered as an intravenous (IV) infusion. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07189455 (Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer), in non-small-cell lung cancer and neuroendocrine tumours. The largest, NCT07189455, plans to enrol 420 participants with primary completion expected 2028-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.